Two medicine make up almost two-thirds of Eli Lilly‘s (NYSE: LLY) high line, producing round $12.8 billion in revenues within the first quarter of 2026. The 2 medicine, Mounjaro and Zepbound, are rising strongly as properly, with gross sales up 125% and 80% 12 months over 12 months, respectively, within the first quarter. So why ought to buyers care that Eli Lilly simply spent $3.8 billion to purchase three vaccine-focused corporations?
The market will get myopically centered at occasions
To make the Mounjaro and Zepbound story much more attention-grabbing, these two medicines are each GLP-1 weight-loss medicine. This can be a scorching new class within the pharmaceutical sector the place Eli Lilly is at present the class chief. Basically, the inventory more and more appears like a one-tick pony, and buyers are comfortable about it, noting that the price-to-earnings ratio is a lofty 39x. The common pharmaceutical inventory has a P/E of round 24x.
Will AI create the world’s first trillionaire? Our workforce simply launched a report on the one little-known firm, referred to as an “Indispensable Monopoly” offering the vital expertise Nvidia and Intel each want. Proceed »
The $3.8 billion Eli Lilly is spending to purchase Curevo, LimmaTech Biologics AG, and Vaccine Firm will rapidly construct its presence within the infectious illness area. Which, for now, will probably be inconsequential to its enterprise. Within the close to time period, buyers will probably be watching Mounjaro, Zepbound, and the corporate’s newly launched GLP-1 capsule, Foundayo. However the massive story that buyers could also be lacking is vital.
Eli Lilly is aware of the drug enterprise properly sufficient to organize forward
The corporate’s GLP-1 portfolio is a vital story, however it’s one which comes with an finish date. That is simply how the pharmaceutical business works, since medicine have time-limited patent safety. Eli Lilly is aware of that the windfall it’s benefiting from proper now will not final eternally. Even when buyers aren’t pondering a decade forward, Eli Lilly is.
That is why constructing an infectious illness enterprise is so vital at present. Whereas it appears like a sideline in comparison with GLP-1 medicine, it’s mainly Eli Lilly benefiting from at present’s success to construct a stronger enterprise over the long run. Whereas there isn’t any strategy to know if any of the three vaccine-focused companies it’s shopping for will flip into massive winners, it’s 100% sure that at present’s GLP-1 success will, sooner or later, fade. Placing one other iron within the hearth with this vaccine funding is just good monetary stewardship.
Eli Lilly is pricey and centered on staying an business chief
Whereas worth buyers will not like Eli Lilly, growth-oriented buyers will probably be interested in it. The GLP-1 story is the core purpose to purchase, together with new varieties of GLP-1 medicine the corporate has within the works which may be much more efficient than its present choices. Nonetheless, administration’s clear intention to leverage its GLP-1 success to create a extra various enterprise might be simply as vital, if no more so. It’s choices like this that result in sustained success over the long run within the drug sector.
